An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

Inclusion Criteria

• Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Must have received and progressed on or failed one standard/approved treatment for cancer type, if available
• At least 4 weeks since any previous treatment for cancer
• Subject must consent to pretreatment and on treatment tumor biopsies
• At least one lesion with measurable disease at baseline
• Adequate organ and marrow function

Exclusion Criteria

• Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted
• Prior organ transplant
• Participants with second/other active cancers requiring current treatment
• Uncontrolled/significant heart disease
• History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
• Active/uncontrolled autoimmune disease
• Active infection

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

• Primary ID CA020-002
• Secondary IDs NCI-2017-00261, 2016-002263-34
• Clinicaltrials.gov ID NCT02913313